Skip to main content
Caplight Logo









Raziel Therapeutics

Raziel Therapeutics

Private
IsraelHealthcare & Life Scienceshttps://www.raziel-therapy.com/

Last Round

Strategic

Jun 28, 2026

Total Funding Raised

$27.1M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Raziel Therapeutics is a clinical-stage pharmaceutical company developing a proprietary injectable compound for non-surgical, targeted fat reduction.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Medical Devices, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

injectable fat reductionbody contouringlipolytic drugnon-surgical fat removalaesthetic medicinesubmental fat treatmentfat dissolving injectionbiopharmaceutical licensingclinical-stage pharmaDercum's diseasekybella alternativemedical aestheticsdrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Raziel Therapeutics Comparables

Compare Raziel Therapeutics with similar companies based on industry and business-model similarity.

Raziel Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Caliway Biopharmaceuticals
87%
AMI Pharm Co., Ltd.
83%
Marllor Biomedical
81%

Raziel Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicJun 28, 2026
StrategicOct 30, 2025
Series CDec 18, 2019
Series AFeb 1, 2016
SeedDec 1, 2014

Raziel Therapeutics Investors

Notable investors and investment history

Raziel Therapeutics investors
InvestorRounds
Israel Innovation AuthoritySeed
Pontifax Venture CapitalSeries A, Series C
Docor International ManagementSeries A, Series C
Catalyst Investments GroupSeries C
Wille Finance AGSeries C
Peregrine VenturesStrategic, Series C
VLX VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 28, 2026

    Raised a strategic round with GC Wellbeing as an investor.

  • Oct 30, 2025

    Raised capital from Peregrine Ventures and 365mc.

Raziel Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Raziel Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Raziel Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersIsrael
Employee Range3
Year Founded2012
Last FundingJun 28, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?